文献速递前列腺癌

近距离放疗联合外照射放疗治疗非转移性前列腺癌的疗效与毒性系统综述

A Systematic Review of the Efficacy and Toxicity of Brachytherapy Boost Combined with External Beam Radiotherapy for Nonmetastatic Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2023-12-26

该系统综述纳入73项研究(2项随机对照试验、7项前瞻性研究、64项回顾性研究),评估近距离放疗联合外照射放疗对比外照射放疗±雄激素剥夺治疗和/或根治性前列腺切除术±术后放疗的疗效与毒性。Meta分析显示联合治疗改善生化无进展生存(HR 0.54,95%CI 0.40-0.72,p<0.001),但无转移生存和总生存无差异,且严重晚期泌尿生殖毒性风险增加。

要点

  • 联合治疗组生化无进展生存优于外照射放疗组(HR 0.54,95%CI 0.40-0.72)。
  • 联合治疗组无转移生存(HR 0.84)和总生存(HR 0.87)与外照射放疗组无显著差异。
  • 联合治疗增加严重晚期泌尿生殖毒性风险,尤其低剂量率联合治疗。

核心结论

  • 对于不利的中危/高危局限期或局部晚期前列腺癌且尿功能良好的患者,可考虑近距离放疗联合外照射放疗,但基于欧洲泌尿外科学会指南方法学的推荐强度为弱推荐,因其基于生化控制的改善。

研究设计与样本

  • 系统综述,检索Ovid MEDLINE、Embase和EBM Reviews-Cochrane Central Register of Controlled Trials数据库2000年1月1日至2022年6月7日发表的文献,纳入73项研究(2项随机对照试验、7项前瞻性研究、64项回顾性研究)。

主要发现

  • 多数研究纳入中危或高危前列腺癌患者,多数研究(包括两项随机对照试验)在联合治疗中使用雄激素剥夺治疗。
  • 联合治疗组生化无进展生存优于外照射放疗组,但无转移生存、肿瘤特异性生存和总生存相似。
  • 两项随机对照试验的Meta分析显示联合治疗组生化无进展生存更优(固定效应HR 0.54,95%CI 0.40-0.72,p<0.001),5-6年生化无进展生存绝对改善4.9-16%。
  • 无转移生存(HR 0.84,95%CI 0.53-1.28,p=0.4)和总生存(HR 0.87,95%CI 0.63-1.19,p=0.4)无差异。
  • 严重晚期泌尿生殖毒性风险增加,尤其低剂量率联合治疗,两项随机对照试验中5-6年严重泌尿生殖毒性患病率增加6.4-7%。

关键数值与推荐

  • 联合治疗组对比外照射放疗组:生化无进展生存HR 0.54(95%CI 0.40-0.72,p<0.001)。
  • 联合治疗组对比外照射放疗组:无转移生存HR 0.84(95%CI 0.53-1.28,p=0.4)。
  • 联合治疗组对比外照射放疗组:总生存HR 0.87(95%CI 0.63-1.19,p=0.4)。
  • 两项随机对照试验中5-6年严重晚期泌尿生殖毒性患病率增加6.4-7%。

临床怎么用

  • 对于不利的中危/高危局限期或局部晚期前列腺癌且尿功能良好的患者,可考虑近距离放疗联合外照射放疗(欧洲泌尿外科学会指南方法学弱推荐)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The optimum use of brachytherapy (BT) combined with external beam radiotherapy (EBRT) for localised/locally advanced prostate cancer (PCa) remains uncertain. OBJECTIVE: To perform a systematic review to determine the benefits and harms of EBRT-BT. EVIDENCE ACQUISITION: Ovid MEDLINE, Embase, and EBM Reviews-Cochrane Central Register of Controlled Trials databases were systematically searched for studies published between January 1, 2000 and June 7, 2022, according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. Eligible studies compared low- or high-dose-rate EBRT-BT against EBRT ± androgen deprivation therapy (ADT) and/or radical prostatectomy (RP) ± postoperative radiotherapy (RP ± EBRT). The main outcomes were biochemical progression-free survival (bPFS), severe late genitourinary (GU)/gastrointestinal toxicity, metastasis-free survival (MFS), cancer-specific survival (CSS), and overall survival (OS), at/beyond 5 yr. Risk of bias was assessed and confounding assessment was performed. A meta-analysis was performed for randomised controlled trials (RCTs). EVIDENCE SYNTHESIS: Seventy-three studies were included (two RCTs, seven prospective studies, and 64 retrospective studies). Most studies included participants with intermediate-or high-risk PCa. Most studies, including both RCTs, used ADT with EBRT-BT. Generally, EBRT-BT was associated with improved bPFS compared with EBRT, but similar MFS, CSS, and OS. A meta-analysis of the two RCTs showed superior bPFS with EBRT-BT (estimated fixed-effect hazard ratio [HR] 0.54 [95% confidence interval {CI} 0.40-0.72], p < 0.001), with absolute improvements in bPFS at 5-6 yr of 4.9-16%. However, no difference was seen for MFS (HR 0.84 [95% CI 0.53-1.28], p = 0.4) or OS (HR 0.87 [95% CI 0.63-1.19], p = 0.4). Fewer studies examined RP ± EBRT. There is an increased risk of severe late GU toxicity, especially with low-dose-rate EBRT-BT, with some evidence of increased prevalence of severe GU toxicity at 5-6 yr of 6.4-7% across the two RCTs. CONCLUSIONS: EBRT-BT can be considered for unfavourable intermediate/high-risk localised/locally advanced PCa in patients with good urinary function, although the strength of this recommendation based on the European Association of Urology guideline methodology is weak given that it is based on improvements in biochemical control. PATIENT SUMMARY: We found good evidence that radiotherapy combined with brachytherapy keeps prostate cancer controlled for longer, but it could lead to worse urinary side effects than radiotherapy without brachytherapy, and its impact on cancer spread and patient survival is less clear.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Slevin F, Zattoni F, Checcucci E, et al. A Systematic Review of the Efficacy and Toxicity of Brachytherapy Boost Combined with External Beam Radiotherapy for Nonmetastatic Prostate Cancer. Eur Urol Oncol. 2023. PMID: 38151440. doi:10.1016/j.euo.2023.11.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。